From Evidence to Practice: Denosumab in Osteoporosis and Joint Health

Main Article Content

Dr SANJAY AGARWALA
Dr DHANANJAY GUPTA
Dr SANJAY YADAV
Dr VIJAY GONI
Dr ANIL MEHTANI
Dr KAMAL BACHANI
Dr SUBHASH JANGID
Dr SUDHIR SETH
Dr NIRAD VEGSARKAR
Dr SHUBHRANSHU SHEKHAR MOHANTY
Dr PRADEEP BHOSALE
Dr HEMANT BHANDARI

Abstract

Osteoporosis and osteopenia are prevalent conditions in India, particularly among postmenopausal women and the elderly,
leading to increased fracture risks and morbidity. Denosumab, a monoclonal antibody, demonstrates superior efficacy
over other treatments in reducing fracture risk and enhancing bone mineral density (BMD). Clinical trials highlight its
effectiveness in preventing periprosthetic bone loss, improving implant stability, and mitigating femoral head collapse in
various conditions; combination therapies involving denosumab further amplify BMD gains and reduce fracture risk. The
article reviews the efficacy and safety of denosumab in managing osteoporosis, joint replacement therapy, and avascular
necrosis based on a review of clinical evidence and studies. Denosumab emerges as a cornerstone therapy for osteoporosis
management, offering multifaceted benefits in fracture prevention, joint replacement therapy, and avascular necrosis.

Article Details

How to Cite
Dr SANJAY AGARWALA, Dr DHANANJAY GUPTA, Dr SANJAY YADAV, Dr VIJAY GONI, Dr ANIL MEHTANI, Dr KAMAL BACHANI, Dr SUBHASH JANGID, Dr SUDHIR SETH, Dr NIRAD VEGSARKAR, Dr SHUBHRANSHU SHEKHAR MOHANTY, Dr PRADEEP BHOSALE, & Dr HEMANT BHANDARI. (2024). From Evidence to Practice: Denosumab in Osteoporosis and Joint Health. Indian Journal Of Clinical Practice, 35(1), 9–14. https://doi.org/10.59793/ijcp.v35i1.1042
Section
Review Article